Is Pfizer Stock a Buy After This $10 Billion Acquisition?

Pfizer (NYSE: PFE) has been southbound for the past three years. Following its success in the coronavirus market, which made it the first company in the biopharma industry to generate $100 billion in annual sales, revenue and earnings have dipped significantly. Furthermore, the drugmaker will face a major patent cliff in the next few years.With all that going on, should investors even consider buying Pfizer's shares? The good news is that the company is looking to right the ship, notably by expanding its pipeline through acquisitions. And the latest one is particularly noteworthy. Let's see if this move makes Pfizer's stock a buy.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool